{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SD+Vaccine", "query": { "intervention": "SD Vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SD+Vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T00:02:50.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05650554", "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Immunization" ], "interventions": [ { "name": "Quadrivalent Influenza mRNA Vaccine MRT5413", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Recombinant Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza Standard Dose Vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza High-Dose Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 682, "start_date": "2022-12-12", "completion_date": "2024-04-02", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 28, "location_summary": "Chula Vista, California • Gardena, California • Long Beach, California + 24 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Gardena", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650554" }, { "nct_id": "NCT00722098", "title": "Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma Stage IV" ], "interventions": [ { "name": "DC Vaccine & Cyclophosphamide", "type": "BIOLOGICAL" }, { "name": "DC Vaccine & Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2008-06", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-07-08", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722098" }, { "nct_id": "NCT05553301", "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Immunization" ], "interventions": [ { "name": "Quadrivalent Influenza mRNA Vaccine MRT5407", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Recombinant Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza Standard Dose Vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza High-Dose Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2022-10-03", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 23, "location_summary": "Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more", "locations": [ { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05553301" }, { "nct_id": "NCT05624606", "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Immunization" ], "interventions": [ { "name": "Quadrivalent Influenza mRNA Vaccine MRT5410", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Recombinant Influenza vaccine RIV4", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Inactivated Influenza Standard Dose QIV-SD", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Inactivated Influenza High Dose QIV-HD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 682, "start_date": "2022-11-28", "completion_date": "2024-03-28", "has_results": false, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 23, "location_summary": "Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more", "locations": [ { "city": "Huntington Park", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05624606" }, { "nct_id": "NCT04613206", "title": "High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunization; Infection", "Transplantation Infection", "Influenza", "Solid Organ Transplant" ], "interventions": [ { "name": "High Dose Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2021-01-11", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04613206" }, { "nct_id": "NCT05514002", "title": "Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Fluzone Quadrivalent", "type": "BIOLOGICAL" }, { "name": "Flublok Quadrivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 3988, "start_date": "2022-09-13", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 4, "location_summary": "Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514002" }, { "nct_id": "NCT01867086", "title": "Salvage Ovarian FANG™ Vaccine + Carboplatinum", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer" ], "interventions": [ { "name": "Vigil™ Vaccine", "type": "BIOLOGICAL" }, { "name": "Carboplatinum", "type": "DRUG" }, { "name": "Carboplatinum and Taxol", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2013-06", "completion_date": "2016-04-08", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01867086" }, { "nct_id": "NCT06744205", "title": "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza", "Healthy Volunteers" ], "interventions": [ { "name": "Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1", "type": "BIOLOGICAL" }, { "name": "TIV mRNA-neuraminidase (NA)", "type": "BIOLOGICAL" }, { "name": "TIV mRNA-HA Vaccine 2", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza Standard Dose Vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Influenza Vaccine High Dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1162, "start_date": "2025-01-06", "completion_date": "2026-05-22", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06744205" }, { "nct_id": "NCT00828009", "title": "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Tecemotide", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-01-17", "completion_date": "2019-05-22", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 88, "location_summary": "Palo Alto, California • Stanford, California • Macon, Georgia + 61 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Macon", "state": "Georgia" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00828009" }, { "nct_id": "NCT01205581", "title": "Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Cancer" ], "interventions": [ { "name": "Fluzone High Dose Vaccine", "type": "BIOLOGICAL" }, { "name": "Fluzone Standard Dose Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 85, "start_date": "2010-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-23", "last_synced_at": "2026-09-03T00:02:50.451Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01205581" } ] }